Study of the renal protective effect of tolvaptan as a replacement of loop diuretics for the treatment of ascites in cirrhotic patients with renal dysfunction

Study of the renal protective effect of tolvaptan as a replacement of loop diuretics for the treatment of ascites in cirrhotic patients with renal dysfunction - Renal protective effect of tolvaptan for cirrhotic patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044693

Enrollment

Registered

2021-07-01

Start date

2021-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

Oral administration of tolvaptan, 3.75 mg-7.5 mg for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with hepatic ascites associated with uncompensated liver cirrhosis who have been taking furosemide for at least 6 months 2. Patients with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min

Exclusion criteria

Exclusion criteria: 1. Patients with active infections, including spontaneous bacterial peritonitis 2. Patients with carcinomatous peritonitis 3. Patients with chronic kidney disease or heart failure 4. Patients with hepatocellular carcinoma or esophagogastric varices within 6 months of treatment 5. Patients receiving vasopressin antagonist 6. Women who are pregnant, potentially pregnant, within 28 days after delivery, or breast-feeding

Design outcomes

Primary

Measure	Time frame
Improvement in eGFR and serum creatinine levels after 12 weeks of administration of tolvaptan	—

Countries

Japan

Contacts

Public ContactTakayuki Kogure

Tohoku Medical and Pharmaceutical University Hospital Gastroenterology

tkogure@med.tohoku.ac.jp022-259-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026